Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings

Zacks11-07

For the quarter ended September 2024, Amphastar Pharmaceuticals (AMPH) reported revenue of $191.21 million, up 5.9% over the same period last year. EPS came in at $0.96, compared to $1.15 in the year-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481084960?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fj4TPQveJWuth16WIsEVAw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be","is_english":true,"pubTime":"2024-11-07 07:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481084960","market":"us","top_or_hot":-1,"title":"Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings","media":"Zacks","content":"<div>\n<p>For the quarter ended September 2024, Amphastar Pharmaceuticals (AMPH) reported revenue of $191.21 million, up 5.9% over the same period last year. EPS came in at $0.96, compared to $1.15 in the year-...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-key-metrics-tell-us-230012936.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 07:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-key-metrics-tell-us-230012936.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the quarter ended September 2024, Amphastar Pharmaceuticals (AMPH) reported revenue of $191.21 million, up 5.9% over the same period last year. EPS came in at $0.96, compared to $1.15 in the year-...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-key-metrics-tell-us-230012936.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMPH","symbol_name":"Amphastar Pharmaceuticals","start_time":0,"source_url":"https://finance.yahoo.com/news/heres-key-metrics-tell-us-230012936.html","article_id":"2481084960","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fj4TPQveJWuth16WIsEVAw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481084960","pubTimestamp":1730934012,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"For the quarter ended September 2024, Amphastar Pharmaceuticals  reported revenue of $191.21 million, up 5.9% over the same period last year. EPS came in at $0.96, compared to $1.15 in the year-ago quarter.The reported revenue represents a surprise of -2.51% over the Zacks Consensus Estimate of $196.15 million. With the consensus EPS estimate being $1.01, the EPS surprise was -4.95%.Net revenues- Epinephrine: $21.34 million compared to the $27.30 million average estimate based on two analysts. The reported number represents a change of +5.7% year over year.Net revenues- Lidocaine: $15.88 million compared to the $13.62 million average estimate based on two analysts. The reported number represents a change of +2.3% year over year.Net revenues- API : $1.46 million compared to the $2.89 million average estimate based on two analysts. The reported number represents a change of -65.1% year over year.Net revenues- Naloxone: $4.04 million compared to the $3.83 million average estimate based on","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AMPH":"Amphastar Pharmaceuticals"},"translate_title":"以下是有关Amphastar(AMPH)第三季度收益的关键指标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMPH":1},"content_text":"For the quarter ended September 2024, Amphastar Pharmaceuticals (AMPH) reported revenue of $191.21 million, up 5.9% over the same period last year. EPS came in at $0.96, compared to $1.15 in the year-ago quarter.\nThe reported revenue represents a surprise of -2.51% over the Zacks Consensus Estimate of $196.15 million. With the consensus EPS estimate being $1.01, the EPS surprise was -4.95%.\nWhile investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.\nSince these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.\nHere is how Amphastar performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: \n\nNet revenues- Primatene MIST: $26.06 million versus $23.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.9% change.\nNet revenues- Epinephrine: $21.34 million compared to the $27.30 million average estimate based on two analysts. The reported number represents a change of +5.7% year over year.\nNet revenues- Lidocaine: $15.88 million compared to the $13.62 million average estimate based on two analysts. The reported number represents a change of +2.3% year over year.\nNet revenues- Phytonadione: $11.72 million versus the two-analyst average estimate of $9.43 million. The reported number represents a year-over-year change of +57.4%.\nNet revenues- API (Active pharmaceutical ingredients): $1.46 million compared to the $2.89 million average estimate based on two analysts. The reported number represents a change of -65.1% year over year.\nNet revenues- Enoxaparin: $5.62 million versus the two-analyst average estimate of $6.08 million. The reported number represents a year-over-year change of -27.1%.\nNet revenues- Naloxone: $4.04 million compared to the $3.83 million average estimate based on two analysts. The reported number represents a change of -14.4% year over year.\nNet revenues- Total finished pharmaceutical products net revenues: $187.36 million versus the two-analyst average estimate of $192.57 million. The reported number represents a year-over-year change of +26.9%.\nNet revenues- Glucagon: $26.79 million versus the two-analyst average estimate of $26.65 million. The reported number represents a year-over-year change of -9.2%.\n View all Key Company Metrics for Amphastar here>>>\n\nShares of Amphastar have returned +11.4% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.\n\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAmphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481084960"}